Menu
 

Search abstracts


Dosage effect of sorafenib in advanced hepatocellular carcinoma treatment

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: HU, Chun-Liang (Tainan Municipal Hospital, pharmacy)
  • Co-author(s): Chun-Liang Hu: Department of pharmacy, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
    Yang-Cheng Lee: Division of Hemato-Oncology, Department of Internal Medicine, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
    Sheng-Kai Lin: Division of Community Service, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
  • Abstract:

    Background

    Sorafenib, an oral multiple tyrosine kinase inhibitor, is the first-line therapy for advanced hepatocellular carcinoma (HCC). When standard dosage (800mg/day) provided, many patients required drug discontinuation or dose reduction due to adverse events (AEs). Some studies reported that starting with a lower sorafenib dose might lead to..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses